Yang Z, Shen X, Zhou C, et al. - Researchers analyzed 54 randomized controlled trials with 4,957 participants, to compare as well as to rank currently available pharmacological interventions for the prophylaxis of recurrent miscarriage (RM) in females suffering from antiphospholipid syndrome (APS). This analysis involved investigations comparing any types of active interventions with placebo/inactive control or another active intervention for RM prophylaxis in patients having APS. According to the findings, low-dose aspirin plus heparin was supported as the first-line therapy for prevention of RM in women with APS. Also, hydroxychloroquine, intravenous immunoglobulin, and prednisone were shown to be efficacious when added to current treatment regimens.